p.o.) or infused into the CA1 region of the dorsal hippocampus 12 h after IA training (Supplementary Figure S1D, E). A similar selective impairment on memory storage was obtained using contextual fear conditioning, another hippocampus-dependent task (Supplementary Figure S1F) .
; i.p.) induced a clear-cut impairment of memory retention at 7 days after training in 5HT-2AR þ / þ , but it did not affect memory in 5HT-2AR À/À mice ( Figure 1e ). These findings are in line with previous data showing that the effects of antidepressants grow with the passage of time, 8 and suggest that an acute antidepressant administration may represent a new and safe tool for hindering persistent memories; in addition, they suggest that pharmacotherapies that activate 5-HT2A receptors in the hippocampus represent potentially useful new strategies to treat these disorders by manipulating the persistence of fear memories. Early discontinuation of antidepressant drugs (ADPs) therapy is common, occurring in about 30% of patients by week 6.
CONFLICT OF INTEREST

1,2
Among the most relevant reasons for ADP discontinuation are adverse drug reactions and lack of improvement, 3 which can be explained by interindividual variability in drug metabolism. Thus, discontinuation of amitriptyline or fluoxetine, two of the most commonly used ADPs worldwide, which are mainly metabolized by CYP2D6, could be related to CYP2D6 genetic polymorphism.
However, little is known about the relationship of CYP2D6 and ADPs discontinuation. Although an absent CYP2D6-mediated poor metabolism (PMs) or ultrarapid metabolism (UM) has been Figure 1 . (a) Attenuation of memory persistence by systemic administration of venlafaxine (V) 11 h after inhibitory avoidance (IA) training; saline (S) injection. Memory was assessed either 2 or 7 days after training. n ¼ 10 animals per group. *Po0.05, student t-test. (b) Same as (a), but here we used immunoblotting to determine the levels of brain-derived neurotrophic factor (BDNF) in the dorsal hippocampus 12 h after training. BDNF/actin ratios were calculated and data are expressed as percentage of control. n ¼ 6 animals per group. **Po0.01, Newman--Keuls test after analysis of variance (ANOVA). (c) Systemic administration of S or V 11 h after IA training. Intrahippocampal infusions of S or MDL11939, a 5-hydroxytryptamine (5-HT)2A receptor antagonist, were given around 11 h after training and infusion of S or human recombinant BDNF were given 12 h after training. Memory was tested 7 days after training n ¼ 10; *Po0.05; ***Po0.001, Newman--Keuls after ANOVA. (d) The same as panel c, but here we assessed BDNF/actin ratios in the dorsal hippocampus 12 h after training. n ¼ 6 animals per group. *Po0.05. (e) V impaired persistence of IA memory storage 7 days after training in 5HT-2AR þ / þ mice but not in 5HT-2AR À/À mice. n ¼ 7--10 animals per group. *Po0.05; Newman--Keuls test after ANOVA. Data are expressed as mean±s.e.m. of training lantency (TR) or test step-down latency.
Letters to the Editor respectively related to higher or lower plasma concentrations of the drug 4 and to toxicity/adverse drug reaction 5, 6 or lack of clinical improvement, 6, 7 only one study has analyzed whether PMs discontinued more from ADPs than the rest. 2 Contrary to expectations, PMs (homozygous carriers of the null activity allele CYP2D6*4) did not discontinue more. This result could be due to two aspects: first, other clinically relevant CYP2D6 allelic variants such as those with null (for example, *3, *5, *6) or reduced activity (e.g., *10, *17) were not analyzed, and some PMs were missed; second, starting ADP doses were at the lower limit of the approved range, which is a common practice nowadays to keep the side effects to a minimum and that may make PMs to tolerate adverse drug reactions. Although this careful and safe way to prescribe ADPs (starting treatment with low doses and increase them gradually if needed) may have the advantage of preventing PMs from discontinuation, 2 it may have the disadvantage of increasing discontinuation in UMs.
The relationship between CYP2D6 genotypes and early discontinuation of ADPs was studied in 100 consecutive patients with major depressive disorder (MDD; DSM-IV criteria) receiving doses of either amitriptyline (at o75 mg; n ¼ 45) or fluoxetine (at 20 mg.; n ¼ 55) in routine clinical practice at the Psychiatric Outpatient Clinics of the Mexican National Institute of Neurology and Neurosurgery. All clinically relevant CYP2D6 alleles and gene multiplications that allow the classification into four functional groups including UMs (Table 1) were analyzed. Written informed consent was obtained from patients. The study was approved by the Mexican National Institute of Neurology and Neurosurgery Ethics Committee, and was conducted in accordance with the Declaration of Helsinki. The CYP2D6 activity value assigned to the reference allele *1 and *2 was 1, to *3, *4, *4xN, *5 and *6 was 0, to *10 or *17 was 0.5 and to multiplications of active alleles (*1xN or *2xN) was 2, 8 allowing the patients classification into four groups according to the number of CYP2D6 active alleles (Table 1) . ADP discontinuation was defined as patient dropout/not followed up at weeks 4, 8 and 12. There were no differences in discontinuation between patients treated with fluoxetine or amitriptyline, although these data are of limited value as the prescription was not randomized like in clinical trial designs.
Despite the limitations of the present study (naturalistic observation, non-fixed dose, lack of evaluation of drug plasma concentrations and efficacy), a relationship between CYP2D6 polymorphism and early discontinuation of fluoxetine or amitriptyline monotherapy treatment was observed. There were differences across CYP2D6 groups in the rate of ADP discontinuation at week 4 (Po0.01; Table 1 ). Overall, the rates of ADP discontinuation were 25, 36 and 46% at weeks 4, 8 and 12, respectively; no patient returned after dropout. All UMs discontinued treatment within the first 4 weeks, whereas no PM did so within 12 weeks.
Although the data about PMs agree with the previous findings, 2 those about UMs are novel. Present data suggest that CYP2D6 may influence discontinuation in UMs when doses at the low end of the range are given. Therefore, future studies should be designed to evaluate different starting doses as well as drug plasma concentrations and effects.
Present results could be also related to the fact that UMs have been shown to present a greater risk of suicide attempts in patients with eating disorders 9 and greater severity of the attempt in suicide survivors, 10 whereas PMs presented a lower risk. 10 In conclusion, CYP2D6 genotyping before ADP treatment with fluoxetine or amitriptyline may contribute to the detection of discontinuation risk, specifically in UMs, if starting doses are at the low end of the range. Letters to the Editor
